Related Experiment Video
Updated: Apr 24, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Uncoupling glucosuria from infection: SGLT2 inhibition modulates kidney immune response during pyelonephritis
Laura Schwartz1, John David Spencer1
1Kidney and Urinary Tract Center, Nationwide Children's Hospital, Columbus, Ohio, USA; The Ohio State University College of Medicine, Department of Pediatrics, Columbus, Ohio, USA.
Abstract:
Sodium-glucose cotransporter 2 inhibitors increase urinary glucose excretion, theoretically predisposing to urinary tract infection, yet clinical trials have not shown higher rates of severe infection. In this issue of Kidney International, Sendtner et al. provide a plausible mechanistic framework for this paradox. Combining human cohort data with experimental pyelonephritis, they demonstrate that sodium-glucose cotransporter 2 inhibition with empagliflozin is associated with reduced C1q expression, preserved antibacterial defenses, and altered inflammatory signaling. These findings suggest that sodium-glucose cotransporter 2 inhibition with empagliflozin may influence kidney antibacterial defenses without increasing infection risk.
Insights
Sodium-glucose cotransporter 2 inhibitors like empagliflozin may not increase severe urinary tract infection risk. Research suggests empagliflozin preserves kidney antibacterial defenses, offering a potential explanation for this clinical observation.
Area of Science:
- Nephrology
- Infectious Diseases
- Pharmacology
Background:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors increase urinary glucose, theoretically raising urinary tract infection (UTI) risk.
- Clinical trials show SGLT2 inhibitors do not increase severe UTI rates, creating a therapeutic paradox.
Purpose of the Study:
- To investigate the mechanistic basis for the observed lack of increased severe UTI risk with SGLT2 inhibition.
- To explore the effects of empagliflozin on kidney antibacterial defenses and inflammatory responses.
Main Methods:
- Analysis of human cohort data.
- Experimental pyelonephritis model in mice.
- Assessment of C1q expression, inflammatory signaling, and antibacterial defenses.
Main Results:
- Empagliflozin treatment was associated with reduced C1q expression in the kidney.
- SGLT2 inhibition preserved key antibacterial defense mechanisms.
- Altered inflammatory signaling pathways were observed in response to empagliflozin.
Conclusions:
- SGLT2 inhibition with empagliflozin may modulate kidney antibacterial defenses.
- These mechanisms could explain the absence of increased severe UTI risk despite increased urinary glucose.
- Empagliflozin may offer a protective effect on kidney infection defense pathways.
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Pyelonephritis I: Introduction
Nephrotic Syndrome I : Introduction
Acute Kidney Injury II: Pathophysiology
Urinary Tract Infection II: Pathophysiology

